These observations have led to the use of a combination of HDACi and PD-L1 inhibitors for the treatment of certain neoplasms, given that the increase in PD-L1 expression renders anti-PD-L1 treatment more effective [61,70,71]. This evidence concerns the gene CD274 and neoplasm.